Loading...
NPI 1972686236 · Keene, NH · Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Cvs Manchester Nh, L.L.C. is a pharmacy provider located in Keene, New Hampshire. This profile covers 11 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Cvs Manchester Nh, L.L.C. |
| Address | 268 West St |
| City | Keene |
| State | NH |
| ZIP | 03431 |
| Taxonomy | Pharmacy |
| NPI Enumerated | October 23, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $374K |
| Medicaid | $150 |
CVS MANCHESTER NH, L.L.C. is registered under the Pharmacy taxonomy and its NPI was enumerated on 2006-10-23 (~20 years ago), indicating long-standing enrollment in federal programs and an established presence in Keene, NH. The provider’s lifetime Medicare revenue is $374K and lifetime Medicaid revenue is $155, showing sustained activity over time but a very small overall Medicaid footprint.
The provider’s Medicare revenue is heavily concentrated: precomputed results show the top 3 Medicare codes account for 70.6% of total Medicare revenue. Those top three are 91322 (41.3% of Medicare revenue, $153.9K), K1034 (17.4% of Medicare revenue, $65K), and 90480 (11.9% of Medicare revenue, $44.2K), which together drive the majority of Medicare dollars reported.
Payer mix is effectively Medicare-dominant: total Medicare revenue of $374K dwarfs Medicaid revenue of $155, so the provider operates with a near single-payer commercial footprint from the perspective of public-program billing. Medicaid billing is negligible in dollar terms and concentrated entirely in a single code line (A4253), which accounts for 100.0% of the provider’s Medicaid revenue.
The code mix reflects a retail-pharmacy service model focused on immunizations and over-the-counter COVID testing rather than office-based evaluation or complex procedural care. High-volume COVID-related items appear throughout the Medicare top list (91322 SARS–CoV–2 vaccine, K1034 COVID self-test provisioning, 90480 vaccine administration), alongside seasonal vaccines such as 90694 (influenza) and pneumococcal codes (90677, G0009), consistent with a community pharmacy offering vaccinations and test distribution.
Operational throughput is visible in claims counts: K1034 shows 5.9K claims and 91322 and 90480 each show about 1.1K claims, indicating substantial volume of low-dollar COVID testing and vaccine administrations. This pattern—large claim counts for K1034 paired with modest per-claim payments—aligns with a pharmacy model that processes many transactions at low average paid/claim amounts.
National competitive standing on key Medicare codes is relatively strong in rank terms but described as typical volume for those codes: 91322 ranks #49 of 29357 providers nationally (100th percentile; typical, unremarkable volume), 90480 ranks #108 of 46950 providers nationally (100th percentile; typical, unremarkable volume), and K1034 ranks #463 of 30143 providers nationally (98th percentile; typical, unremarkable volume). These ranks indicate the provider is among the more active billers nationally for these vaccination and test codes, but the data labels this activity as within expected ranges for similar providers.
On Medicaid, the business impact is limited and narrowly focused: A4253 (blood glucose test strips) accounts for 100.0% of the provider’s Medicaid revenue, with 101 claims and $202 total revenue, and ranks #6 of 15 providers in-state (64th percentile; typical, unremarkable volume). This suggests the provider participates in at least one Medicaid supply line but is not a dominant statewide Medicaid supplier.
Beyond the three largest Medicare codes, the provider reports additional vaccine-related Medicare revenue streams—90694 (influenza, $37.8K, 10.1% of Medicare revenue) and G0008 (influenza administration, $25.4K, 6.8% of Medicare revenue) among others—indicating diversified vaccination offerings that supplement the COVID-focused activity and contribute meaningful secondary revenue lines.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
11 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 1,080 | $140 | $153.9K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 5,910 | $10 | $65K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 1,080 | $40 | $44.2K |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 500 | $80 | $37.8K |
| G0008 | Administration of influenza virus vaccine | 820 | $30 | $25.4K |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 280 | $70 | $20.2K |
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 50 | $280 | $13.7K |
| 0134A | N/A | 260 | $40 | $10.8K |
| G0009 | Administration of pneumococcal vaccine | 50 | $10 | $730 |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 20 | $20 | $530 |
Showing 1–10 of 11
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 11 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| A4253 | Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips | 100 | $1 | $200 |
How this provider's Medicaid billing volume and revenue compare to other New Hampshire providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New Hampshire median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| A4253 | Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips | 6 | 20 | 60 | $1 | $280 |
Other providers in the same ZIP code as Cvs Manchester Nh, L.L.C., ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.